DATRELL WARD: Open Payments
NPI 1386024776 · LANHAM, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$395 in 17 payments from 7 companies in 2025. Trend: 2023 $99 · 2024 $17 · 2025 $395
Food & beverage: $395
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $113 |
| Alkermes, Inc. | 6 | $109 |
| Neurocrine BioSciences, Inc. | 2 | $60 |
| Janssen Pharmaceuticals, Inc | 1 | $45 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| ABBVIE INC. | 1 | $18 |
Products named: UZEDY, ARISTADA, INGREZZA, INVEGA SUSTENNA, ABILIFY MAINTENA, COBENFY, VRAYLAR, AUSTEDO XR.
Industry payments across MD — which companies pay providers there.
